Advertisement

A critical review of pyritinol

  • Alok SinghEmail author
  • Vinay Purohit
Review Article
  • 7 Downloads

Abstract

Pyritinol (pyrithioxine) is a combination of two molecules of vitamin B6 (pyridoxine) with disulfide linkage. Its pharmacokinetic profile mimics that of its parent compound. Because it crosses the blood–brain barrier, its major clinical utility is in brain-related disorders. Pyritinol regulates signalling pathways of various neurotransmitters including acetylcholine, γ-aminobutyric acid, N-methyl-d-aspartate, etc. Pyritinol has also been shown to act as an antioxidant and anti-inflammatory agent, and also reduces plasma viscosity. It is indicated in paediatric populations to treat learning disabilities, developmental dysphasia, postnatal hypoxia and other cognitive disorders. In adults, it is indicated for improving cognition and memory, Alzheimer’s disease, multi-infarct dementia and rheumatoid arthritis. It has also been investigated in many other clinical conditions, but results are inconclusive. The positive results of many animal studies have not been replicated into consistent clinical success. This review aims to discuss potential uses of pyritinol and its future prospects.

Notes

Compliance with ethical standards

Conflict of interest

Authors declare no conflicts of interest relevant to this article.

Funding

No funding received from any source.

References

  1. 1.
    Maria V, Albuquerque A, Loureiro A, et al. Severe cholestatic hepatitis induced by pyritinol. BMJ. 2004;328(7439):572–4.CrossRefGoogle Scholar
  2. 2.
    Alkuraishy HM, Al-Gareeb AI, Albuhadilly AK. Vinpocetine and pyritinol: a new model for blood rheological modulation in cerebrovascular disorders—a randomized controlled clinical study. BioMed Res Int. 2014;2014:324307.  https://doi.org/10.1155/2014/324307.CrossRefGoogle Scholar
  3. 3.
    Liu JM, Wu PF, Rao J, et al. ST09, a novel thioester derivative of tacrine, alleviates cognitive deficits and enhances glucose metabolism in vascular dementia rats. CNS Neurosci Ther. 2016;22(3):220–9.CrossRefGoogle Scholar
  4. 4.
    Jiménez-Andrade GY, Reyes-García G, Sereno G, et al. Pyritinol reduces nociception and oxidative stress in diabetic rats. Eur J Pharmacol. 2008;590(1–3):170–6.CrossRefGoogle Scholar
  5. 5.
    Magnusson KR, Brim BL, Das SR. Selective vulnerabilities of N-methyl-d-aspartate (NMDA) receptors during brain aging. Front Aging Neurosci. 2010;2:11.  https://doi.org/10.3389/fnagi.2010.00011.Google Scholar
  6. 6.
    Turský T. Pyritinol inhibition of the GABA and benzodiazepine receptor. Physiol Bohemoslov. 1988;37(5):417–26.Google Scholar
  7. 7.
    Seth SD, Seth V, editors. Textbook of pharmacology. 3rd ed. New Delhi: Elsevier; 2009.Google Scholar
  8. 8.
    Jebasingh D, Devavaram Jackson D, Venkataraman S, et al. The protective effects of Cyperus rotundus on behavior and cognitive function in a rat model of hypoxia injury. Pharm Biol. 2014;52(12):1558–69.CrossRefGoogle Scholar
  9. 9.
    Jaiswal AK, Upadhyay SN, Bhattacharya SK. Effect of pyritinol, a cerebral protector, on learning and memory deficits induced by prenatal undernutrition and environmental impoverishment in young rats. Indian J Exp Biol. 1990;28(7):609–15.Google Scholar
  10. 10.
    Floersheim GL. Protection against acute ethanol toxicity in mice by zinc aspartate, glycols, levulose and pyritinol. Agents Actions. 1985;16(6):580–4.CrossRefGoogle Scholar
  11. 11.
    Dayrens P, Ivanoff B, Cussac M, et al. Antiinflammatory and immunostimulant activities of six sulphur compounds—four benzenesulphonates, levamisole, and pyritinol hydrochloride—assayed in mouse cell activation studies. Arzneimittelforschung. 1983;33(3):372–7.Google Scholar
  12. 12.
    De Guibert C, Maumet C, Jannin P, et al. Abnormal functional lateralization and activity of language brain areas in typical specific language impairment (developmental dysphasia). Brain. 2011;134(10):3044–58.CrossRefGoogle Scholar
  13. 13.
    Zavadenko NN, Kozlova EV, Koltunov IE. Developmental dysphasia: assessment of the drug treatment efficacy (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(7 Pt 2):90–5.Google Scholar
  14. 14.
    Zavadenko NN, Kozlova EV. Nootropic drug therapy for developmental dysphasia in children (in Russian). Voprosy Prakticheskoi Pediatrii. 2013;8(5):24–8.Google Scholar
  15. 15.
    Nair MK, George B, Jeyaseelan L. Pyritinol for post asphyxial encephalopathy in term babies: a randomized double-blind controlled trial. Indian Pediatr. 2009;46(Suppl):s37–42.Google Scholar
  16. 16.
    Zykov VP, Begasheva OI. Cognitive disturbances in patients with tics and Tourette’s syndrome and their correction with encephabol (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova. 2003;103(11):10–4.Google Scholar
  17. 17.
    Zenkov LR, Zenkova AL. Encephabol in the treatment of cognitive disorders in epilepsy (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(5 Pt 2):77–80.Google Scholar
  18. 18.
    Hindmarch I, Coleston DM, Kerr JS. Psychopharmacological effects of pyritinol in normal volunteers. Neuropsychobiology. 1990–1991;24(3):159–64.Google Scholar
  19. 19.
    Mufson JE, Counts SE, Perez SE, et al. Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications. Expert Rev Neurother. 2008;8(11):1703–18.CrossRefGoogle Scholar
  20. 20.
    Ballinger E, Ananth M, Talmage DA, et al. Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline. Neuron. 2016;91(6):1199–218.CrossRefGoogle Scholar
  21. 21.
    Fischhof PK, Saletu B, Rüther E, et al. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). Neuropsychobiology. 1992;26(1–2):65–70.CrossRefGoogle Scholar
  22. 22.
    Knezevic S. Pyritinol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements. Int Clin Psychopharmacol. 1989;4(1):25–38.CrossRefGoogle Scholar
  23. 23.
    Herrmann WM, Kern U, Röhmel J. On the effects of pyritinol on functional deficits of patients with organic mental disorders. Pharmacopsychiatry. 1986;19(5):378–85.CrossRefGoogle Scholar
  24. 24.
    Wiese JG, Shilpak MG, Browner WS. The alcohol hangover. Ann Intern Med. 2000;132:897–902.CrossRefGoogle Scholar
  25. 25.
    Khan MA, Jensen K, Krogh HJ. Alcohol-induced hangover: a double-blind comparison of pyritinol and placebo in preventing hangover symptoms. Q J Stud Alcohol. 1973;34(4):1195–201.Google Scholar
  26. 26.
    Shah A, St. Clair EW. Rheumatoid arthritis. Harrison’s principles of internal medicine. 20th ed. New York: McGraw-Hill Education; 2018.Google Scholar
  27. 27.
    Lemmel EM. Comparison of pyritinol and auranofin in the treatment of rheumatoid arthritis. The European Multicenter Study Group. Br J Rheumatol. 1993;32(5):375–82.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PharmacologyAll India Institute of Medical SciencesRaipurIndia
  2. 2.Procter and GambleMumbaiIndia

Personalised recommendations